ASX - By Stock
|
RCE |
Re:
[INTERVIEW] Recce gearing up for Indonesian trials
|
|
Rykster
|
20 |
6.2K |
1 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
20
|
6.2K
|
1
|
|
ASX - By Stock
|
TLS |
Re:
Where to now for long term investors of Telstra
|
|
Rykster
|
12K |
6.8M |
3 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
12K
|
6.8M
|
3
|
|
ASX - By Stock
|
VRC |
Re:
FUTURE POTENTIAL V3
|
|
Rykster
|
705 |
237K |
6 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
705
|
237K
|
6
|
|
ASX - By Stock
|
CCZ |
Re:
Copper price
|
|
Rykster
|
2 |
875 |
1 |
26/04/24 |
26/04/24 |
ASX - By Stock
|
2
|
875
|
1
|
|
ASX - By Stock
|
VRC |
Re:
Ann: Volt Secures Funding
|
|
Rykster
|
23 |
6.6K |
3 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
23
|
6.6K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Rykster
|
44 |
14K |
2 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
44
|
14K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Rykster
|
44 |
14K |
8 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
44
|
14K
|
8
|
|
ASX - By Stock
|
VRC |
Re:
Asimwe Kabunga
|
|
Rykster
|
5 |
1.9K |
7 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
5
|
1.9K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
Rykster
|
22 |
7.6K |
4 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
22
|
7.6K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
Rykster
|
22 |
7.6K |
2 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
22
|
7.6K
|
2
|
|
ASX - By Stock
|
VRC |
Re:
Ann: Volt and AETC Enter into Agreement
|
|
Rykster
|
44 |
17K |
4 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
44
|
17K
|
4
|
|
ASX - By Stock
|
VRC |
Re:
Ann: Volt and AETC Enter into Agreement
|
|
Rykster
|
44 |
17K |
6 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
44
|
17K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Patent Granted in Israel for RECCE Anti-Infectives
|
|
Rykster
|
8 |
3.1K |
6 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
8
|
3.1K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Rykster
|
48 |
14K |
0 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
48
|
14K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Rykster
|
48 |
14K |
4 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
48
|
14K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Rykster
|
48 |
14K |
3 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
48
|
14K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Rykster
|
48 |
14K |
1 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Rykster
|
48 |
14K |
4 |
16/03/24 |
16/03/24 |
ASX - By Stock
|
48
|
14K
|
4
|
|
ASX - By Stock
|
VRC |
Re:
Ann: VRC Identifies Site for Natural Graphite Production Facility
|
|
Rykster
|
27 |
8.2K |
4 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
27
|
8.2K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Rykster
|
39 |
8.3K |
4 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
39
|
8.3K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
Rykster
|
38 |
10K |
2 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
38
|
10K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] Recce Pharmaceuticals secures AUD$11.18M from Endpoints Capital
|
|
Rykster
|
3 |
749 |
3 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
3
|
749
|
3
|
|
ASX - By Stock
|
EXL |
Re:
News: EXL Elixinol Wellness Reconfirms FY24 Revenue Guidance Of A$16M - A$20M
|
|
Rykster
|
2 |
742 |
2 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
2
|
742
|
2
|
|
ASX - By Stock
|
QGL |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
Rykster
|
18 |
5.6K |
1 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
18
|
5.6K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] RCE teams with leading Indonesian biomed company for anti-infective push
|
|
Rykster
|
25 |
7.4K |
1 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
25
|
7.4K
|
1
|
|
ASX - By Stock
|
EXL |
Re:
Ann: Binding Agreement to Divest Non-core Asset
|
|
Rykster
|
4 |
1.7K |
5 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
4
|
1.7K
|
5
|
|
ASX - By Stock
|
HMX |
Re:
Ann: Commencing Preliminary Discussions
|
|
Rykster
|
98 |
33K |
6 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
98
|
33K
|
6
|
|
ASX - By Stock
|
HMX |
Re:
Ann: Li - Au Drill Program Commences at Yandal Project
|
|
Rykster
|
79 |
27K |
3 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
79
|
27K
|
3
|
|
ASX - By Stock
|
HMX |
Re:
Ann: Li - Au Drill Program Commences at Yandal Project
|
|
Rykster
|
79 |
27K |
2 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
79
|
27K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] RCE teams with leading Indonesian biomed company for anti-infective push
|
|
Rykster
|
25 |
7.4K |
4 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
25
|
7.4K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] RCE teams with leading Indonesian biomed company for anti-infective push
|
|
Rykster
|
25 |
7.4K |
4 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
25
|
7.4K
|
4
|
|
ASX - By Stock
|
EXL |
Re:
Ann: Trading Halt
|
|
Rykster
|
4 |
1.6K |
2 |
12/02/24 |
12/02/24 |
ASX - By Stock
|
4
|
1.6K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Establishes Strategic Partnership in South-East Asia
|
|
Rykster
|
48 |
12K |
1 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
48
|
12K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Establishes Strategic Partnership in South-East Asia
|
|
Rykster
|
48 |
12K |
4 |
07/02/24 |
07/02/24 |
ASX - By Stock
|
48
|
12K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Establishes Strategic Partnership in South-East Asia
|
|
Rykster
|
48 |
12K |
3 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
48
|
12K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Rykster
|
15 |
4.8K |
4 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
15
|
4.8K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion
|
|
Rykster
|
34 |
12K |
1 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
34
|
12K
|
1
|
|
ASX - By Stock
|
VRC |
Re:
Ann: Bunyu Graphite Sample Delivered
|
|
Rykster
|
18 |
7.1K |
6 |
23/01/24 |
23/01/24 |
ASX - By Stock
|
18
|
7.1K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion
|
|
Rykster
|
34 |
12K |
5 |
20/01/24 |
20/01/24 |
ASX - By Stock
|
34
|
12K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion
|
|
Rykster
|
34 |
12K |
1 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
34
|
12K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Murdoch Children's R327 Efficacy UTI in-vivo
|
|
Rykster
|
27 |
10K |
4 |
28/12/23 |
28/12/23 |
ASX - By Stock
|
27
|
10K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Awarded Further $11.17m Advanced Overseas Finding
|
|
Rykster
|
28 |
8.3K |
1 |
20/12/23 |
20/12/23 |
ASX - By Stock
|
28
|
8.3K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Awarded Further $11.17m Advanced Overseas Finding
|
|
Rykster
|
28 |
8.3K |
2 |
20/12/23 |
20/12/23 |
ASX - By Stock
|
28
|
8.3K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Awarded Further $11.17m Advanced Overseas Finding
|
|
Rykster
|
28 |
8.3K |
1 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
28
|
8.3K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Acurx Pharmaceuticals
|
|
Rykster
|
28 |
9.1K |
0 |
08/12/23 |
08/12/23 |
ASX - By Stock
|
28
|
9.1K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Acurx Pharmaceuticals
|
|
Rykster
|
28 |
9.1K |
3 |
07/12/23 |
07/12/23 |
ASX - By Stock
|
28
|
9.1K
|
3
|
|
ASX - By Stock
|
CCZ |
Re:
Going no where
|
|
Rykster
|
72 |
36K |
1 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
72
|
36K
|
1
|
|
ASX - By Stock
|
VRC |
Re:
Ann: Volt Reports Significant Progress on Downstream Business
|
|
Rykster
|
25 |
8.4K |
5 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
25
|
8.4K
|
5
|
|
ASX - By Stock
|
HMX |
Re:
Ann: Mount Isa East JV Drill Testing of Multiple Targets Underway
|
|
Rykster
|
39 |
14K |
10 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
39
|
14K
|
10
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Canadian Patent Granted for RECCE Anti-Infectives
|
|
Rykster
|
14 |
6.1K |
5 |
25/11/23 |
25/11/23 |
ASX - By Stock
|
14
|
6.1K
|
5
|
|